ArticleBMC rheumatology2026
Effectiveness of IV cyclophosphamide and mycophenolate mofetil in the treatment of childhood-onset lupus nephritis in a resource-limited setting.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLupus nephritis (LN) is a major cause of morbidity in childhood-onset systemic lupus erythematosus (cSLE). Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are recommended first-line induction therapies, yet comparative pediatric real-world data, particularly from Asian populations, remain limited. This study compared the effectiveness of CYC and MMF for induction of renal remission and evaluated patterns and predictors of treatment switching among Filipino children with LN.
methodsWe performed a retrospective cohort study of children with LN treated at a tertiary hospital. Patients received CYC using the NIH intravenous protocol or standard-dose MMF. Complete renal response (CRR) was defined as proteinuria < 0.5 g/day (UPCR < 500 mg/g) with stable renal function. Incidence rates were calculated using person-time methods. Time-to-CRR was analyzed using Kaplan–Meier curves with log-rank testing. Logistic regression identified predictors of treatment switching.
resultsA total of 231 patients were included. Baseline disease severity was greater in the CYC group, with higher proteinuria and more frequent Class IV nephritis. Overall CRR incidence was 4.86 per 100 person-months (95% CI 4.18–5.62), with similar rates between CYC and MMF (4.91 vs. 4.71; p = 0.818). CRR occurred in 77.0% and 84.2% of patients, respectively, and median time-to-CRR did not differ significantly (13 vs. 24 months; p = 0.431). Treatment switching was common, mainly due to inadequate response, and occurred more frequently with MMF. Rituximab was used in refractory cases. Female sex and tuberculosis increased the likelihood of switching, whereas higher prednisone dose and rituximab use were protective. No patients progressed to end-stage kidney disease.
conclusionsCYC and MMF showed comparable effectiveness for induction of childhood-onset LN. Frequent treatment modification reflects individualized, real-world management. Prospective multicenter studies are warranted to optimize pediatric treatment strategies. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.